Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
ST. LOUIS, March 15, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced the opening of its new facility in Wuxi, China, that will provide localized packaging, analytical services and quality control for high-quality products to support the Company's research and industrial customers in the region.
"Over the last decade China has invested heavily in industrial growth, and now we are viewing a similar expansion in China's healthcare, pharmaceuticals and life-science markets," said Rakesh Sachdev, Sigma-Aldrich President and CEO. "A core part of our Company's growth strategy is to invest in high growth emerging markets and expanding our global footprint. China represents a significant opportunity for Sigma-Aldrich and the establishment of our presence in Wuxi demonstrates our long-term commitment toward this rapidly growing market."
The new facility sits on approximately 20 acres of land and includes a dedicated quality control center, a state-of-the-art analytical application laboratory and packaging building. The Wuxi campus provides a platform for future expansion of products and services.
"Our investment in the Wuxi New District is a logical evolution that underlines our commitment to our customers and reinforces China as a strategic regional supply chain hub for Asia-Pacific," said Eric Green, Sigma-Aldrich Vice President and Managing Director, International. "The Wuxi site further enables us to provide high quality products with higher service levels and a broader product portfolio tailored for the local markets."
The opening of the new multi-million dollar facility was inaugurated on March 13 in a ceremony attended by Sachdev and Green and more than 150 guests including senior government officials and key customers.
Cautionary Statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "will make," "will provide," or similar expressions, or by expressed or implied discussions regarding potential future outcomes from the facility derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that this facility will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding the facility could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 40 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at http://www.sigma-aldrich.com/.
Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co. LLC registered in the US and other countries.